Innovation thérapeutique et enjeux capacitaires en médecine nucléaire : la situation de la RIV en Occitanie

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a chronic disease with a lethal prognosis within two years of diagnosis. PSMA-radioligand therapy (RLT) represents an efficient and well-tolerated therapeutic innovation that enhances survival and quality of life for patients with this condition. However, the diffusion of this technology can be hindered by a number of obstacles. With 1500 patients already eligible for this treatment and 120 new patients added each year, the adoption and spread of PSMA-RLT in the Occitanie region represent a significant challenge for resource planning. In this context, private nuclear medicine (NM), which accounts for over half of all practicing NM physicians, can enhance a healthcare offer that, at best, covers less than two thirds of the needs of the region's inhabitants.